|
I don't think they want to learn more about the ES risks, so they are claiming ignorance, but it is based on their policy of rejecting ES.
Embryonic stem-cell trial put on hold
Future clinical test still waiting for the go-ahead.
Monya Baker
The first potential clinical trial of a cell therapy derived from embryonic stem (ES) cells has been put on hold by the US Food and Drug Administration (FDA). Researchers say this reflects the still-unknown risks of such treatments in humans.
Biotech company Geron in Menlo Park, California, has been talking to the FDA for more than four years over its proposal to inject patients who have spinal cord injuries with oligodendroglial progenitor cells grown from ES cells. The company announced last week that it had received a “clinical hold” on its application, but that the FDA has not yet disclosed the reasons why.
Researchers are unsure whether the agency’s action reflects specific problems with Geron’s trial or more general concerns about the safety of all ES-cell-derived therapies, in which case other pending trials might also be delayed. To enter trials, companies will need to provide convincing data that the transplanted cells are safe, and particularly that no undesirable cells will cause tumours or other harm, says Ole Isacson, a neuroscientist at Harvard Medical School.
snip
Awaiting approval The hold comes a month after the FDA held its first advisory meeting on how best to evaluate products derived from ES cells. Industry analyst Steven Brozak of WBB Securities in San Diego, California, worries that the decision for the hold was motivated by political objections to ES-cell research, but researchers in the field discount this, saying that the agency is genuinely uncertain about how to ensure safety.
snip
|